Tag: Arthrosi Therapeutics

Arthrosi Secures $153 Million in Series E Financing to Complete Pivotal Development of Pozdeutinurad for the Treatment of Gout and Tophaceous Gout

Arthrosi Secures $153 Million in Series E Financing to Complete Pivotal Development of Pozdeutinurad for the Treatment of Gout and Tophaceous Gout

SAN DIEGO, Oct. 8, 2025 /PRNewswire/ — Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in…

Read More Read More

Arthrosi Therapeutics has filed a notice of an exempt offering of securities to raise $75,000,000.00 in New Equity Investment.

Arthrosi Therapeutics has filed a notice of an exempt offering of securities to raise $75,000,000.00 in New Equity Investment.

According to filings with the U.S. Securities and Exchange Commission, Arthrosi Therapeutics is raising up to $75,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Litain Yeh played a…

Read More Read More

Arthrosi Therapeutics has filed a notice of an exempt offering of securities to raise $20,000,000.00 in New Equity Investment.

Arthrosi Therapeutics has filed a notice of an exempt offering of securities to raise $20,000,000.00 in New Equity Investment.

According to filings with the U.S. Securities and Exchange Commission, Arthrosi Therapeutics is raising $20,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Litain Yeh played a key role…

Read More Read More